C WorldWide Group Holding A S reduced its stake in shares of Endologix, Inc. (NASDAQ:ELGX) by 4.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 501,006 shares of the medical instruments supplier’s stock after selling 23,550 shares during the period. C WorldWide Group Holding A S’s holdings in Endologix were worth $2,435,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of ELGX. Trexquant Investment LP bought a new position in shares of Endologix during the first quarter valued at approximately $376,000. Parametric Portfolio Associates LLC increased its position in Endologix by 30.0% in the first quarter. Parametric Portfolio Associates LLC now owns 89,748 shares of the medical instruments supplier’s stock valued at $650,000 after buying an additional 20,685 shares during the last quarter. Stoneridge Investment Partners LLC increased its position in Endologix by 142.4% in the first quarter. Stoneridge Investment Partners LLC now owns 196,344 shares of the medical instruments supplier’s stock valued at $1,422,000 after buying an additional 115,337 shares during the last quarter. Great West Life Assurance Co. Can increased its position in Endologix by 6,604.0% in the first quarter. Great West Life Assurance Co. Can now owns 448,025 shares of the medical instruments supplier’s stock valued at $3,249,000 after buying an additional 441,342 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in Endologix by 7.6% in the first quarter. Wells Fargo & Company MN now owns 157,990 shares of the medical instruments supplier’s stock valued at $1,144,000 after buying an additional 11,188 shares during the last quarter.

Endologix, Inc. (ELGX) opened at 4.28 on Friday. Endologix, Inc. has a 52 week low of $4.08 and a 52 week high of $13.30. The company’s market cap is $357.10 million. The company’s 50-day moving average is $4.82 and its 200-day moving average is $5.96.

Endologix (NASDAQ:ELGX) last announced its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.08. Endologix had a negative net margin of 40.77% and a negative return on equity of 46.32%. The company had revenue of $48.60 million during the quarter, compared to analysts’ expectations of $47.58 million. During the same quarter in the prior year, the company earned ($0.20) EPS. The firm’s revenue was down 4.6% on a year-over-year basis. On average, analysts anticipate that Endologix, Inc. will post ($0.62) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/12/c-worldwide-group-holding-a-s-lowers-position-in-endologix-inc-nasdaqelgx.html.

Several equities analysts have recently issued reports on ELGX shares. Zacks Investment Research downgraded shares of Endologix from a “hold” rating to a “sell” rating in a research note on Tuesday, April 25th. Royal Bank Of Canada reaffirmed a “hold” rating and set a $5.00 price target on shares of Endologix in a research note on Monday, July 31st. Canaccord Genuity reaffirmed a “hold” rating and set a $5.00 price target on shares of Endologix in a research note on Thursday, May 18th. Stifel Nicolaus reaffirmed a “buy” rating and set a $5.50 price target (up previously from $5.00) on shares of Endologix in a research note on Monday, June 5th. Finally, Oppenheimer Holdings, Inc. set a $5.00 price target on shares of Endologix and gave the company a “hold” rating in a research note on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating and eleven have given a hold rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $6.28.

In other news, Director Dan Lemaitre purchased 22,522 shares of the stock in a transaction that occurred on Monday, May 22nd. The stock was bought at an average cost of $4.43 per share, for a total transaction of $99,772.46. Following the acquisition, the director now directly owns 68,689 shares of the company’s stock, valued at approximately $304,292.27. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Guido J. Neels purchased 20,000 shares of the stock in a transaction that occurred on Friday, May 19th. The shares were purchased at an average price of $4.32 per share, with a total value of $86,400.00. Following the completion of the acquisition, the director now directly owns 61,380 shares in the company, valued at $265,161.60. The disclosure for this purchase can be found here. Insiders have purchased a total of 44,722 shares of company stock valued at $195,676 over the last quarter. 3.90% of the stock is currently owned by company insiders.

Endologix Company Profile

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Want to see what other hedge funds are holding ELGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endologix, Inc. (NASDAQ:ELGX).

Institutional Ownership by Quarter for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.